Solid-phase extraction and fractionation of multiclass pollutants from wastewater followed by liquid chromatography tandem-mass spectrometry analysis

V. Fernández-Fernández1 · M. Ramil1 · R. Cela1 · I. Rodríguez1

Received: 9 February 2022 / Revised: 1 April 2022 / Accepted: 5 April 2022 / Published online: 23 April 2022 © The Author(s) 2022

Abstract
Herein, we describe a modular solid-phase extraction (SPE) setup, combining three sorbents, for the effective extraction of neutrals, acidic, and basic micropollutants from wastewater, followed by their further elution in three independent extracts. The performance of this approach was demonstrated for a suite of 64 compounds, corresponding to different chemical families, using liquid chromatography tandem-mass spectrometry (LC–MS/MS). Target compounds were effectively extracted from wastewater samples; moreover, 62 out of 64 species were isolated in just one of the three fractions (neutrals, acids, and bases) obtained from the combination of sorbents. Globally, the efficiency and the selectivity of the SPE methodology improved the features obtained using generic SPE polymers, displaying just reversed-phase interactions. The overall recoveries of the analytical method, calculated against solvent-based calibration standards, stayed between 80 and 120% for 57 and 60 compounds, in raw and treated wastewater, respectively. Procedural limits of quantification (LOQs) varied from 1 to 20 ng L\(^{-1}\). Analysis of urban wastewater samples identified a group of 19 pollutants showing either negligible median removal efficiencies (± 20%) during wastewater treatment, or even a noticeable enhancement (case of the biodegradation product of the drug valsartan), which might be useful as markers of wastewater discharges in the aquatic environment.

Keywords Wastewater · Modular solid-phase extraction · Fractionation · Liquid chromatography tandem-mass spectrometry

Introduction
The number of organic compounds of environmental and toxicological concern has increased steadily for the last 20 years. Many of them are introduced in the aquatic environment through urban wastewater [1, 2]. Most of the analytical procedures for the monitoring of these compounds are based on mass spectrometry (MS), combined with different chromatographic techniques, after an extraction and concentration step [3]. In this regard, the hydrophilic-lipophilic balanced (HLB) solid-phase extraction (SPE) sorbents cover the effective extraction of compounds within a broad range of polarities from water samples. Thus, they are usually employed in combination with multianalyte/multiclass liquid chromatography (LC) MS-based methods [4–6]. The price of their high retention efficiency is a limited selectivity, which turns in significant variations in the efficiency of compound ionization (particularly using electro-spray ionization, ESI) between sample extracts and solvent-based standards [6]. The so-called matrix effects (MEs) do not only affect the accuracy of the obtained results, but also compound detectability since, in most cases, their ionization efficiency is attenuated for sample extracts when compared to solvent-based standards [5].

Mixed-mode (MM) sorbents, sharing ionic and reversed-phase (RP) interactions, improve the recoveries of highly polar, ionizable compounds in comparison to RP polymers, maintaining an acceptable retention efficiency for neutrals [7, 8]. Moreover, they allow the use of fractionated elution protocols, recovering compounds retained through the RP mechanism and those establishing electrostatic interactions with sorbent in different fractions [9]. Thus, cleaner extracts are obtained for the latter group of compounds, which turns in lower MEs [10–12]. The scientific literature contains previous successful
applications of different types of MM sorbents to the selective extraction of basic (i.e., illicit drugs [13] and pharmaceuticals [11]), or acidic compounds (such as anti-hypertension drugs [12] and perfluorinated carboxylic and sulfonic acids [14]) from water samples. Most of these studies have been compiled in a recent review [7]. However, using conventional MM sorbents, the isolation of acidic and basic compounds in two separate fractions, requires two independent SPE extractions, with different MM polymers. In both assays, neutrals are mixed, either with basic or with acidic species.

In order to combine high retention efficiencies during the concentration step with fractionated elution protocols, different alternatives are under evaluation. Zwitterionic MM sorbents permitted the removal of neutrals, in a washing fraction, whilst acids and bases were recovered together [15]. Another possibility involves the combination of different types of sorbents, either packed in the same cartridge, or connected in tandem. This approach was reported to improve the extraction efficiency of low molecular size, polar, and ionizable compounds, poorly retained in RP materials; however, in these previous studies, the sequential elution of compounds in independent fractions was not investigated [8, 16]; consequently, extracts presented a high complexity. Using a multilayered cartridge setup (based on different combinations of conventional MM sorbents), Salas et al. [17] demonstrated the possibility to retain and to recover quantitatively a selection of 13 compounds in neutral, acidic, and basic fractions. In that study, the retention efficiency and the success of the fractionated elution protocol depended on the type of MM sorbents, and their relative proportions in the in-house packed cartridge [17].

The aim of this research was to develop a modular SPE approach, based on tandem combinations of commercially available cartridges, covering the effective extraction and the further fractionated elution of a suite of 64 compounds (log $D$ values from −1.95 to 5.5) attending to their ionizable groups: acids, bases, and neutrals, from wastewater samples. Sorbents were maintained in separate cartridges to increase the versatility of the elution protocol. Each SPE fraction was analyzed using different LC–MS/MS procedures, finely tuned to enhance compound detectability and to reduce blank contamination problems. The performance of the method was characterized in terms of extraction efficiency, MEs, and accuracy. Thereafter, it was applied to determine the levels of target compounds in raw and treated wastewater samples obtained from urban sewage treatment plants (STPs).

**Material and methods**

**Solvents, sorbents, and standards**

Methanol (MeOH) and acetonitrile (ACN), both LC–MS grade; formic acid (FA, LC–MS grade); ammonia (NH$_3$, 7 M solution in MeOH); and ammonium fluoride (NH$_4$F) were purchased from Merck (Darmstadt, Germany). Ultra-pure deionized water (18.2 MΩ cm$^{-1}$) was obtained from a Genie U system (Rephile, Shanghai, China).

RP OASIS HLB 60-mg and 200-mg cartridges, and 150-mg MM cartridges (MCX, RP, and strong cationic exchange sorbent; and WAX, RP, and weak anionic exchange sorbent) were provided by Waters (Milford, MA, USA). Ionic exchange 500-mg cartridges containing either sulfonic functionalities (SCX), or quaternary amines (SAX), as charged groups bonded to silica particles, were obtained from Agilent (Santa Clara, CA, USA).

Native standards of species involved in this research were purchased from Sigma-Aldrich (St. Louis, MO, USA). Compounds were selected attending to their environmental and/or toxicological concern, including species compiled in the 2020 revision of the EU Watch List of contaminants to control in the aquatic environment [18]. The suite of compounds includes species without ionizable groups (neutrals, i.e., organophosphorus compounds and certain neonicotinoids), weak (phenols) and strong acids (carboxylic, tetrazolic, sulfonic, etc.), weak and strong bases (i.e., azoles and tertiary amines, respectively), and pollutants combining acidic and basic functionalities in the same molecule (e.g., certain angiotensin receptor antagonists, ARA-II, as losartan). The list of analytes, including their log $D$ values and their categorization as acids, bases, or neutrals, is given in Table 1. Individual stock solutions of each compound were prepared in MeOH, except in case of neonicotinoids (ACN). Further dilutions and mixtures were also made in MeOH. Stock solutions and diluted mixtures were maintained at −20 °C and used throughout this study. The exception was perfluorinated carboxylic acids. Their methanolic solutions were renewed every month to prevent esterification of the carboxylic moiety [19].

A selection of isotopically labeled compounds (either deuterated or $^{13}$C species) was obtained from Merck and Toronto Research Chemicals (North York, Canada), either as pure compounds, or as stocks in MeOH (usually 100–1000 μg mL$^{-1}$, Table S1). Mixtures of these species were also made in MeOH. They were added to water samples, as surrogate standards (SSs), before SPE extraction. Solvent-based calibration standards were prepared in MeOH, or MeOH to FA (99:1) case of acidic species, in the range of concentrations from 0.5 to 300 ng mL$^{-1}$. The concentration of SSs in calibration standards was 50 ng mL$^{-1}$.

**Samples and sample preparation**

Wastewater was obtained from four different urban STPs in Galicia (Northwest Spain). All of them apply similar wastewater treatments involving primary and biological (activated sludge) units. Grab samples were used during
Table 1 Summary of target compounds, including LC–ESI–MS/MS determination conditions, instrumental LOQs, and linearity evaluation

| Group                | Compound name                      | Precursor ion | Q1 (CE) | Q2 (CE) | Ratio (Q2/Q1) | Ret time (min) | IS        | ESI          | Log D(pH 7) | LOQs (ng/mL) | Linearity (R²) |
|----------------------|------------------------------------|---------------|---------|---------|---------------|----------------|-----------|-------------|-------------|--------------|----------------|
| Acids                | 2,4-Dichlorophenoxyacetic acid     | 251.1         | 161.0(12)| 25.0(32)| 0.08          | 6.66           | 2,4-Dichlorophenoxyacetic acid-d₅ | -           | -1.14        | 2              | 0.992        |
|                      | 4-(2,4-Dichlorophenoxy)butyric acid| 247.0         | 161.0(4) | 38.0(52)| 0.11          | 9.04           | 2,4-Dichlorophenoxyacetic acid-d₅ | -           | 0.97         | 2              | 0.990        |
| Cardiovascular       | Candesartan                        | 441.1         | 235.1(28)| 82.1(32)| 0.90          | 8.17           | Irbesartan-d₄       | +           | 0.59         | 0.3            | 0.995        |
|                      | Eprosartan                         | 425.1         | 135.1(36)| 97.1(28)| 0.30          | 8.10           | Irbesartan-d₄       | +           | -0.57        | 0.3            | 0.997        |
|                      | Irbesartan acid                    | 429.3         | 207.1(24)| 38.5(24)| 0.17          | 9.71           | Irbesartan-d₄       | +           | 3.31         | 0.3            | 0.998        |
|                      | Losartan                           | 425.2         | 207.1(28)| 96.2(28)| 0.37          | 9.22           | Irbesartan-d₄       | +           | 1.51         | 0.2            | 0.997        |
|                      | 2-Methyl-4-chlorophenoxyacetic acid| 199.0         | 140.8(12)| 38.1(48)| 0.15          | 6.85           | 2,4-Dichlorophenoxyacetic acid-d₅ | -           | -1.3         | 1              | 0.996        |
|                      | Mecoprop                           | 213.0         | 140.8(12)| 38.1(48)| 0.13          | 7.60           | Irbesartan-d₄       | +           | -0.92        | 1              | 0.996        |
|                      | Olmesartan                         | 447.2         | 207.1(24)| 429.2(9)| 0.54          | 7.60           | Irbesartan-d₄       | +           | -0.78        | 0.2            | 0.997        |
|                      | Perfluoropropanoic acid            | 165.0         | 118.8(12)| 48.9(40)| 0.02          | 1.18           | Perfluoropropanoic acid-13C₂ | -           | -1.33        | 0.2            | 0.999        |
|                      | Perfluorobutanoic acid             | 213.0         | 169.0(5) | n.a      | -             | 2.27           | Perfluoropropanoic acid-13C₂ | -           | -0.36        | 0.1            | 0.999        |
|                      | Perfluorobutanoic acid-d₄          | 296.0         | 200.0(51)| 90.0(55)| 0.37          | 6.99           | Perfluorobutanoic acid-13C₂ | -           | -1.81        | 0.1            | 0.997        |
|                      | Perfluoronitric acid               | 415.0         | 365.1(17)| 107.0(3)| 0.30          | 9.90           | Perfluoronitric acid-13C₄ | -           | 2.69         | 0.1            | 0.996        |
|                      | Perfluoronitric acid-d₄            | 499.0         | 385.0(51)| 90.0(56)| 0.30          | 10.45          | Perfluoronitric acid-13C₄ | -           | 1.01         | 0.4            | 0.998        |
|                      | Telmisartan                        | 516.1         | 497.2(40)| 275.1(40)| 0.48          | 9.72           | Irbesartan-d₄       | +           | 3.65         | 0.2            | 0.996        |
|                      | Valsartan                          | 426.2         | 207.1(28)| 251.1(28)| 0.98          | 9.00           | Irbesartan-d₄       | +           | -0.68        | 0.2            | 0.996        |
|                      | Valsartan acid                     | 267.1         | 206.1(20)| 176.1(36)| 0.58          | 6.62           | Valsartan-d₄       | +           | -1.95        | 0.1            | 0.998        |
| Group | Compound name | Precursor ion | Q1 (CE) | Q2 (CE) | Ratio (Q2/Q1) | Ret time (min) | IS | ESI | Log DpH? | LOQs (ng/mL) | Limit of detection (ng/mL) |
|-------|---------------|---------------|---------|---------|---------------|----------------|----|-----|---------|-------------|--------------------------|
| Bases| Acetamiprida | 223.1 | 126.0 (27) | 56.1 (12) | 0.41 | 5.69 | Acetamiprid-d3 | + | 1.55 | 0.1 | 0.999 |
|       | Amitriptyline | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Amitriptyline-d5 | + | 1.02 | 0.1 | 0.999 |
|       | Clozapine | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Clozapine-d5 | + | 2.6 | 0.1 | 0.999 |
|       | Clemazol | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Clemazol-d4 | + | 2.6 | 0.1 | 0.999 |
|       | Clopenthixol | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Clopenthixol-d4 | + | 2.6 | 0.1 | 0.999 |
|       | Clotrimazole | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Clotrimazole-d5 | + | 2.6 | 0.1 | 0.999 |
|       | Fenticonazole | 182.1 | 128.1 (36) | 128.1 (36) | 0.63 | 10.10 | Miconazole-d5 | + | 4.56 | 0.1 | 0.999 |
|       | Flecainide | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Flecainide-d4 | + | 2.6 | 0.1 | 0.999 |
|       | Flucloxacillin | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Flucloxacillin-d4 | + | 2.6 | 0.1 | 0.999 |
|       | Imidacloprid | 182.1 | 128.1 (36) | 128.1 (36) | 0.63 | 10.10 | Miconazole-d5 | + | 4.56 | 0.1 | 0.999 |
|       | Lamotrigine | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Lamotrigine-d3 | + | 2.6 | 0.1 | 0.999 |
|       | Metconazole | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Metconazole-d4 | + | 2.6 | 0.1 | 0.999 |
|       | Miconazole | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Miconazole-d5 | + | 2.6 | 0.1 | 0.999 |
|       | N-Desethyl amiodarone | 617.9 | 72.1 (28) | 546.9 (24) | 0.47 | 10.15 | Miconazole-d5 | + | 5.51 | 0.1 | 0.999 |
|       | N-Desmethylnorfaconazole | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Norfaconazole-d5 | + | 2.6 | 0.1 | 0.999 |
|       | N-Desmethyl citalopram | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | N-Desmethyl citalopram-d5 | + | 2.6 | 0.1 | 0.999 |
|       | Norsertraline | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Norsertraline-d5 | + | 2.6 | 0.1 | 0.999 |
|       | O-Desmethyl venlafaxine | 264.1 | 58.1 (17) | 246.2 (13) | 0.25 | 4.59 | Venlafaxine-d5 | + | 0.37 | 0.1 | 0.999 |
|       | Penconazole | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Penconazole-d5 | + | 2.6 | 0.1 | 0.999 |
|       | Prochloraz | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Prochloraz-d5 | + | 2.6 | 0.1 | 0.999 |
|       | Propiconazole | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Propiconazole-d5 | + | 2.6 | 0.1 | 0.999 |
|       | Sertraline | 378.1 | 302.1 (16) | 126.1 (16) | 0.28 | 6.53 | Sertraline-d5 | + | 2.6 | 0.1 | 0.999 |
method development. Integrated (24-h time proportional) samples were employed to measure the concentrations of target compounds, and to evaluate their removal efficiencies during wastewater treatment. Samples were received in glass bottles, sequentially passed through quartz (0.7-μm cutoff) and cellulose acetate filters (0.45-μm pore-size), and stored at 4 °C, for a maximum of 24 h, before extraction.

During method development, different combinations of sorbents were tested. Under final working conditions, a modular SPE setup consisting of a MM 150 mg WAX cartridge (top) on-line connected to a RP 60 mg HLB one (bottom) was employed. Samples (100 mL volume aliquots), spiked with SSs and adjusted at neutral pH (6.5–7.5) when required, were passed through both cartridges at a flowrate of c.a. 5 mL min⁻¹. After washing sample containers and connections with SPE sorbents, using 10 mL of ultrapure water, cartridges were dried using a gentle stream of nitrogen and connected to an ionic exchange (SCX) one, previously conditioned with MeOH. Neutrals and weak acids were recovered with MeOH flowing through the three sorbents (extract volume 5 mL). After disconnecting the three cartridges, compounds with a strong acidic functionality (carboxylic, sulfonic, or tetrazolic groups) were recovered from the WAX cartridge with 2 mL of MeOH to NH₃ (98:2). Basic species were eluted from the SCX one using 5 mL of MeOH to NH₃ (95:5) (Fig. 1). Every extract was evaporated and adjusted to a final volume of 1 mL; moreover, that from the WAX sorbent was acidified with 0.020 mL of FA. Reference SPE extractions were carried out using RP HLB cartridges (200 mg sorbent), for the concentration of 100 mL samples. In this case, all compounds were recovered in the same fraction of methanol (5 mL), which was further concentrated to 1 mL. Extracts were filtered (0.22-μm pore-size syringe filter) before LC–MS/MS analysis.

**LC–MS/MS determination conditions**

Compounds were determined using an ultra-performance liquid chromatography (UPLC) triple quadrupole-type MS system provided by Agilent. The UPLC was 1290 Infinity II connected through a jet-stream ESI source to an i-funnel Agilent 6495 QqQ instrument. Different analytical (LC or UPLC) and delay columns were employed for the separation of target compounds, and to discriminate responses for contaminants existing in the mobile phase from those corresponding to injected compounds. Detailed UPLC conditions for each group of compounds, including type of columns, mobile phase composition, flowrate, and column temperature are compiled in Table S2. The injection volume was set at 2 μL in all methods. Voltages of the ESI source were 3000 V and 2000 V for positive and negative ionization modes, respectively. The fragmentor voltage was 166 V and the MRM parameters for each compound, including
ionization mode and ratio between qualification (Q2) and quantification (Q1) transitions, are compiled in Table 1. In a few cases (e.g., perfluorobutanoic acid and tramadol, TRA), only one transition was available. MRM parameters for compounds employed as SSs are given in Table S1.

In addition to the QqQ system, a time-of-flight (TOF) instrument (Agilent 6550) was employed to investigate the distribution of additional compounds in the SPE fractions obtained from non-spiked wastewater samples. In this case, the pseudo-molecular ions ([M + H]⁺ or [M − H]⁻) of each species were extracted using a mass window of 20 ppm. Compound identities were further confirmed against authentic standards. In this case, the employed LC conditions were those reported in Table S2 for basic species.

**Extraction efficiency, matrix effects, and accuracy evaluation**

The extraction efficiency (EEs, %) of the modular SPE protocol described in “Samples and sample preparation” (accounting for yields of extraction, fractionated elution, and extract concentration to 1 mL) was assessed as the ratio of responses (peak area for the Q1 transition without SSs correction) obtained for spiked wastewater aliquots and spiked SPE extracts multiplied by 100. Matrix effects (MEs, %) during ESI were evaluated comparing the difference of responses for spiked and non-spiked extracts of each sample (raw and treated wastewater) with those observed for a solvent-based standard of the same concentration. Values close to 100% correspond to similar ionization efficiencies for sample extracts versus solvent-based standards. On the other hand, normalized response ratios below and above 100% mean suppression and enhancement of compound ionization in sample extracts versus solvent-based standards [20]. The above parameters (EEs and MEs) were evaluated using an additional level of 1 ng mL⁻¹ referred to the water sample (equivalent to 100 ng mL⁻¹ in the corresponding SPE extract).

The accuracy of the final procedure was investigated using samples spiked at three levels: 50, 200, and 1000 ng L⁻¹. For each type of wastewater, non-spiked (n = 3 replicates) and spiked fractions (n = 3, for each addition level) were fortified with SSs (500 ng L⁻¹) and processed as reported in “Samples and sample preparation.” Responses obtained for each compound were corrected with that measured to the assigned SS (Table 1), and compared to those obtained for solvent-based standards (concentration range from 0.5 to 300 ng mL⁻¹).

Two different kinds of blanks were considered during method development and application. Instrumental blanks corresponded to simulated (false) injections. That is, the injection valve changes from the by-pass to the main-pass

![Fig. 1 Scheme of sample concentration and elution steps in the modular solid-phase extraction procedure](image-url)
position, with the mobile phase flowing through the injector loop and the injection needle to the LC column; however, the autosampler does not select any vial (sample, procedural blank, standard or solvent). These experiments permitted identifying contamination problems related to the UPLC system and/or the mobile phase (mainly the aqueous phase). Procedural blanks were prepared using ultrapure water samples, spiked only with the selection of SSs, and submitted to the adopted modular SPE protocol. This type of blanks is useful to detect contamination problems related to the sample preparation process.

Instrumental limits of quantification (LOQs) were calculated as the concentration of each compound producing a response with a signal to noise ratio (S/N) of 10 for the less intense of the selected transitions (usually Q2) in solvent-based standards. Procedural LOQs were estimated from instrumental LOQs, considering a 100-fold concentration factor, corrected with EEs and MEs when they were outside the range of values between 80 and 120%. Moreover, for compounds found in the procedural blanks, the LOQs of the method were calculated as the average concentration measured in blank extracts plus 10 times its standard deviation.

Results and discussion

LC–ESI–MS/MS conditions

Three LC-QqQ-MS methods were employed to enhance the detectability of each group of considered compounds (acids, bases, and neutrals). In case of IMI and ACE, their transitions were included in methods developed for neutral and basic species. Except for TCS, the rest of neutrals and bases were determined in ESI (+); thus, FA was used as mobile phase modifier (0.1%) to promote their ionization. ACN, instead of MeOH, was preferred as organic mobile phase to reduce the retention of some highly lipophilic organophosphate flame retardants included in the group of neutrals, and to decrease the pressure in the UPLC system considering that two identical columns (delay and analytical columns) were required to cope with instrumental blanks noticed for some compounds within this group.

As regards acidic compounds, FA (0.1%) and NH₄F (1 mM) were tested as mobile phase additives. The ARA-II drugs showed a higher ionization efficiency under ESI (+). On the other hand, herbicides and perfluorinated compounds led only to their [M−H]⁻ ions. Thus, ESI (+) and ESI (−) modes were combined in this method. Depending on the type of modifier, differences between 20 and 40% in responses obtained for herbicides and perfluorinated compounds were noticed. However, most ARA-II drugs rendered one order of magnitude higher responses using NH₄F as modifier (Fig. S1).

The instrumental LOQs of compounds considered in this research were not only conditioned by their ionization efficiencies, but also by the existence of instrumental contamination sources. These problems were noticed in LC–MS/MS records obtained for simulated injections. Particularly, mobile phases contributed significantly to the presence of several perfluorinated and organophosphate compounds in instrumental blanks. To discriminate the response due to instrumental contamination from that of the standard, delay columns were connected between the mobile phase mixer and the injector of the UPLC system. These columns are described in Table S2. Fig. S2 illustrates the separation of the chromatographic peak (earlier signal) for a low concentration standard of selected compounds: tris(2-chloro-isopropyl) phosphate (TCP), tributoxyethyl phosphate (TBP), and perfluorooctanoic acid (PFOA), from that corresponding to mobile phase contamination (latter peak), after installing the corresponding delay column.

Under final working conditions, the LC–ESI–MS/MS methods achieved instrumental LOQs in the range from 0.1 to 0.5 ng mL⁻¹ for most of the target compounds. In all cases, linear responses were attained for concentrations up to 300 ng mL⁻¹ (Table 1).

Solid-phase extraction and fractionation of multiclass pollutants from wastewater followed… 4155

Preliminary SPE experiments were carried out using spiked aliquots of ultrapure water, considering different combinations of sorbents. The first tested setup involved retention of the suite of compounds (neutrals, acids, and bases) in a MM MCX sorbent [9]. In this case, samples were adjusted at pH 3 to improve the retention of highly polar, acidic species, in the MCX sorbent, through RP interactions. Neutrals are expected to be retained by the same mechanism and bases through electrostatic interactions with negatively charged sites of the polymer. Obviously, the latter interactions are favored in acidified samples. During the elution step, the MCX cartridge was connected to an anionic exchange (SAX) one. Distribution of compounds was investigated in the following solvent fractions: MeOH (5 mL) flowing through both cartridges connected in series, MeOH to NH₄⁺ (95:5) recovered from the upper MCX sorbent (after removing the SAX one), and MeOH to FA (95:5) collected from the SAX cartridge. Under these conditions, neither the retention nor the fractionation of neutrals and acidic compounds was satisfactory. As example, the short-chain perfluorinated compounds (C₃ carboxylic acid and C₄ carboxylic and sulfonic acids) were not retained by the MCX sorbent; so, their EEs remained below 20%. Compounds with acidic and basic moieties in their structures (i.e., most of the ARA-II pharmaceuticals) were found in the fraction of basic drugs, whilst acidic drugs (e.g., valsartan, VAL, and valsartan acid,
VALA), herbicides (phenoxy acids), and C₈ perfluorinated compounds eluted together with neutrals in the methanolic fraction. That is, they were not fractionated from neutrals by the SAX sorbent. To sum up, this setup did not show any advantage compared to the single use of the MM MCX sorbent, enabling the fractionated elution of bases from neutral and acids.

The second SPE setup considered concentration of water samples, at neutral pH, using a weak anionic exchange MM sorbent (WAX) [12]. In the elution step, this sorbent was connected to a pure cationic exchanger (SCX) cartridge. As in the former case, three different fractions were collected. MeOH was passed through both cartridges connected in series to recover neutrals. Thereafter, they were disconnected and eluted with MeOH to NH₃ (98:2). Above 95% of the responses (peak areas) observed for the suite of selected compounds was noticed in the expected SPE fraction according to their preliminary classification given in Table 1. The only exceptions were the neonicotinoid insecticides imidacloprid (IMI) and acetamiprid (ACE), distributed between the neutral and the basic fractions in similar percentages.

On view of these preliminary results, the second setup was adopted, and retention and elution conditions were re-evaluated using spiked wastewater samples. Some highly polar and basic species, such as TRA, venlafaxine (VEN) and O-desmethyl venlafaxine (O-DVEN), citalopram (CIT), and N-desmethyl citalopram (N-DCIT) (their log D values ranged from −0.4 to 1.0 at neutral pH, Table 1), were not retained quantitatively by the WAX sorbent. For 100 mL volume wastewater samples, between 5 and 18% of the responses measured for these compounds were noticed in the extract from a second WAX cartridge on-line connected to the first one. In order to improve their retention, the mixed-mode WAX cartridge was combined (placed on top) with 60 mg HLB one to reinforce the RP retention mechanism during sample concentration. As regards the volume and the type of solvents employed in the fractionated elution protocol, 5 mL of MeOH was passed through the ternary combination of sorbents (MM, RP, and strong cationic exchange) to recover neutrals (Fig. 1). Triclosan (TCS), selected as representative of weak acidic phenolic species (predicted pKa 7.8), was also quantitatively eluted in this fraction. Again, IMI and ACE were partially retained by the SCX sorbent, being detected in neutral and, mostly, basic fractions. The other two neonicotinoids included in the study (thiamethoxam, THM, and clothianidin, CLO) were found only in the neutral fraction (methanolic extract). Likely, the chlorononicinotic ring existing in the structures of IMI and ACE leads to a weak interaction of both compounds with the strong anionic exchange sorbent. None of the tested acidic compounds was released from the WAX cartridge during elution of neutrals. So, the HLB cartridge was discarded after this step (Fig. 1). Acids were recovered using just 2 mL of MeOH with a 2% of NH₃, which is in agreement with the data published by G. Castro and co-workers [12] for SPE of ARA-II species using WAX cartridges. Finally, basic compounds showed a strong interaction with the SCX sorbent. Their quantitative elution (particularly in case of those containing tertiary amine groups) was required to increase the percentage of NH₃ added to MeOH from 2 to 5%, using 5 mL of this mixture.

**Performance of the method**

The EEs of the sample preparation process, calculated as defined in “Extraction efficiency, matrix effects, and accuracy evaluation,” are summarized in Table 2. For most compounds, EEs ranged from 80 to 120%. In a few cases, values between 70 and 130% were noticed. On the other hand, six compounds showed non-quantitative extraction yields. Within the group of bases, EEs around 50% were observed for the pharmaceuticals: fenticonazole, miconazole, and sertaconazole, and the drug metabolite N-desethyl amiodarone. The four are relatively lipophilic compounds, with log D values above 4.5 (Table 1). Very likely, non-quantitative EEs are the result of sorption losses on glassware and connections with SPE cartridges. Although it was attempted to improve their recoveries by addition of MeOH to the water samples (10–20 mL of methanol per 100 mL of sample), this approach led to retention problems for polar basic species, positively charged at neutral pH values. Since the latter ones have a higher potential to be present in the water phase than more lipophilic drugs, no organic solvent was added to samples before SPE. The 2nd group of compounds displaying non-satisfactory recoveries was the neonicotinoids IMI and ACE. As commented in “LC–ESI–MS/MS conditions,” both species were distributed between neutral and basic fractions. In raw wastewater, the overall EEs for each group of pollutants were 94% (acids), 91% (bases) and 86% (neutrals). For treated wastewater, average SPE EEs were 96%, 76%, and 94% for acids, bases, and neutrals, respectively.

The selectivity of the modular SPE methodology was assessed comparing the responses obtained for the three groups of compounds in spiked extracts from raw and treated wastewater, with those corresponding to solvent-based standards prepared in MeOH [20]. Moreover, the normalized response ratios were compared to those obtained using a HLB sorbent, applied to 100 mL aliquots of the same water samples. In case of acids, most species showed normalized responses in the range from 80 to 120% (Fig. 2A). The only exception was VALA affected by moderate (68%) and strong signal suppression (44%) effects in the modular SPE and HLB extracts, respectively (Fig. 2A). It is worth noting that, for acidic compounds, the RP methodology (based on the use of an HLB 200-mg cartridge for concentration of 100-mL samples) failed to
Table 2  Extraction efficiencies for spiked samples of raw and treated wastewater using the modular SPE procedure, $n=3$ replicates

| Group       | Compound                                      | Raw wastewater | Treated wastewater | Group       | Compound                                      | Raw wastewater | Treated wastewater |
|-------------|-----------------------------------------------|----------------|-------------------|-------------|-----------------------------------------------|----------------|-------------------|
|             | Mean RSDs (%)                                 | Mean RSDs (%)  |                   |             | Mean RSDs (%)                                 | Mean RSDs (%)  |                   |
| Acids       | 2,4-Dichlorophenoxyacetic acid                | 97% 3%         | 102% 1%           | Bases       | Metconazole                                   | 97% 4%         | 84% 4%            |
|             | 4-(2,4-Dichlorophenoxy) butyric acid         | 97% 7%         | 99% 5%            |             | Miconazole                                    | 52% 19%        | 67% 1%            |
|             | Candesartan                                   | 88% 2%         | 99% 2%            |             | Myclobutan                                   | 102% 4%        | 88% 5%            |
|             | Eprosartan                                    | 97% 3%         | 96% 2%            |             | N-Desethyl amiodarone                         | 42% 22%        | 64% 4%            |
|             | Fenoprop                                      | 101% 5%        | 100% 2%           |             | N-Desethyl citalopram                         | 93% 3%         | 81% 5%            |
|             | Irbesartan                                    | 92% 2%         | 97% 2%            |             | Norsertraline                                 | 75% 8%         | 75% 4%            |
|             | Losartan                                      | 88% 3%         | 95% 4%            |             | O-Desethyl venlafaxine                        | 118% 3%        | 94% 4%            |
|             | 2-Methyl-4-chlorophenoxyacetic acid          | 98% 6%         | 97% 3%            |             | Penconazole                                   | 103% 3%        | 85% 5%            |
|             | Mecroprop                                     | 98% 8%         | 101% 3%           |             | Prochloraz                                    | 90% 5%         | 79% 4%            |
|             | Olmesartan                                    | 98% 3%         | 99% 2%            |             | Propiconazole                                 | 97% 4%         | 85% 5%            |
|             | Pentafluoropropanoic acid                    | 83% 3%         | 82% 4%            |             | Propanolol                                    | 101% 3%        | 82% 4%            |
|             | Perfluorobutanoic acid                        | 88% 3%         | 100% 2%           |             | Sertaconazole                                 | 42% 29%        | 65% 2%            |
|             | Perfluorobutanoic acid sulfonic acid         | 92% 4%         | 102% 3%           |             | Serumaline                                    | 90% 3%         | 77% 2%            |
|             | Perfluorooctanoic acid                        | 86% 1%         | 116% 5%           |             | Tefubconazole                                 | 98% 2%         | 84% 4%            |
|             | Perfluorooctanoic acid sulfonic acid         | 88% 4%         | 75% 2%            |             | Terbutryn                                     | 100% 3%        | 79% 3%            |
|             | Telmisartan                                   | 92% 3%         | 97% 2%            |             | Tetraconazole                                 | 100% 4%        | 86% 5%            |
|             | Valsartan acid                                | 104% 3%        | 84% 4%            |             | Thiamidazole                                  | 128% 15%       | 85% 5%            |
|             | Valsartan                                    | 106% 2%        | 94% 3%            |             | Ticloconazole                                 | 71% 9%         | 70% 2%            |
| Bases       | Acetamiprid                                   | 61% 19%        | 57% 17%           |             | Tramadol                                      | 113% 3%        | 87% 5%            |
|             | Amitriptyline                                 | 102% 4%        | 79% 3%            |             | Trizodone                                     | 94% 4%         | 75% 5%            |
|             | Citalopram                                    | 105% 5%        | 82% 4%            |             | Venlafaxine                                   | 112% 3%        | 86% 5%            |
|             | Climbazole                                   | 96% 3%         | 82% 4%            | Neutrals    | Clothianidin                                  | 94% 4%         | 95% 2%            |
|             | Clomipramine                                  | 94% 3%         | 73% 3%            |             | Cresyl diphenyl phosphate                     | 80% 8%         | 84% 5%            |
|             | Cloperastine                                  | 91% 4%         | 20% 31%           |             | Dimoxystrobin                                 | 89% 5%         | 99% 4%            |
|             | Clotrimazole                                  | 80% 6%         | 71% 2%            |             | Octyl isothiazolinone                         | 81% 7%         | 85% 7%            |
|             | Fentinonazole                                 | 57% 26%        | 53% 5%            |             | Tris(2-Chloroethyl) phosphate                 | 87% 7%         | 101% 2%           |
|             | Flecaainide                                   | 110% 5%        | 87% 4%            |             | Tris(1-Chloro-2-propyl) phosphate             | 85% 13%        | 106% 4%           |
|             | Fluconazole                                   | 105% 4%        | 87% 5%            |             | Triclosan                                     | 87% 12%        | 79% 5%            |
|             | Haloperidol                                   | 109% 7%        | 79% 4%            |             | Thiamethoxam                                  | 86% 3%         | 96% 2%            |
|             | Imazalil                                      | 102% 6%        | 80% 3%            |             | Tributosylethyl phosphate                     | 93% 7%         | 105% 5%           |
|             | Imidacloprid                                  | 45% 15%        | 56% 21%           |             | Tributyl phosphate                            | 77% 10%        | 96% 3%            |
|             | Lamotrigine                                   | 118% 5%        | 88% 4%            |             | Triphenyl phosphate                           | 90% 19%        | 92% 4%            |
Fig. 2 Comparison of matrix effects (MEs, %) obtained for the different groups of compounds using modular and direct (reversed-phase extraction) SPE approaches for raw wastewater concentrated 100 times. A Acids. B Bases. C Neutrals. D Distribution of ME values in raw and treated wastewater as function of the solid-phase extraction protocol.
Table 3  Average accuracy of the procedure for spiked wastewater samples ($n=9$ samples spiked at 3 concentration levels: 50, 200, and 1000 ng L$^{-1}$) and estimated procedural LOQs

| Compound                        | Raw wastewater | Treated wastewater | LOQs ng L$^{-1}$ |
|---------------------------------|----------------|--------------------|------------------|
|                                 | Average  RSD (%) | Min | Max | Average RSD (%) | Min | Max |               |
| Acids                           |                |      |     |                |      |     |               |
| 2,4-Dichlorophenoxyacetic acid  | 94% 5%         | 89% | 100% | 102% 1%        | 1%  | 101% | 104% 20      |
| 4-(2,4-Dichlorophenoxy)butyric acid | 93% 6%       | 86% | 97%  | 96% 5%         | 5%  | 91%  | 100% 20      |
| Candesartan                     | 77% 5%         | 73% | 82%  | 88% 8%         | 8%  | 80%  | 95% 5        |
| Eprosartan                      | 89% 9%         | 84% | 100% | 92% 4%         | 4%  | 89%  | 96% 5        |
| Fenoprop                        | 103% 3%        | 99% | 105% | 99% 4%         | 4%  | 96%  | 104% 10      |
| Irbesartan                      | 106% 6%        | 100%| 111% | 105% 6%        | 6%  | 99%  | 111% 2       |
| Losartan                        | 89% 11%        | 78% | 100% | 101% 12%       | 12% | 93%  | 114% 5       |
| 2-Methyl-4-chlorophenoxyacetic acid | 96% 9%        | 86% | 104% | 98% 6%         | 6%  | 91%  | 104% 10      |
| Mecoprop                        | 105% 5%        | 99% | 109% | 105% 3%        | 3%  | 102% | 107% 10      |
| Olmesartan                      | 90% 4%         | 86% | 94%  | 101% 11%       | 11% | 92%  | 113% 5       |
| Pentafluoropropanoic acid       | 96% 9%         | 87% | 105% | 100% 14%       | 14% | 85%  | 113% 10      |
| Perfluorobutanoic acid          | 84% 4%         | 80% | 87%  | 104% 13%       | 13% | 93%  | 119% 10      |
| Perfluorobutano sulfonic acid   | 111% 12%       | 104%| 125% | 109% 7%        | 7%  | 105% | 117% 2       |
| Perfluorooctanoic acid          | 90% 1%         | 89% | 91%  | 103% 9%        | 9%  | 95%  | 112% 10      |
| Perfluorooctano sulfonic acid   | 96% 4%         | 91% | 99%  | 100% 4%        | 4%  | 97%  | 104% 5       |
| Telmisartan                     | 108% 14%       | 92% | 120% | 107% 11%       | 11% | 100% | 119% 5       |
| Valsartan acid                  | 100% 13%       | 87% | 112% | 101% 18%       | 18% | 81%  | 116% 5       |
| Valsartan                       | 98% 10%        | 89% | 109% | 96% 9%         | 9%  | 86%  | 103% 2       |
| Compound               | Raw wastewater | Treated wastewater | LOQs ng L<sup>-1</sup> |
|------------------------|----------------|-------------------|-------------------------|
|                        | Average | RSD (%) | Min | Max | Average | RSD (%) | Min | Max |                  |
| Acetamiprid            | 105%    | 1%      | 100%| 110%| 100%    | 5%      | 95% | 105%|                  |
| Amitriptyline          | 95%     | 7%      | 90% | 103%| 99%     | 5%      | 94% | 103%| 2                  |
| Citalopram             | 89%     | 8%      | 81% | 96% | 103%    | 9%      | 92% | 109%| 3                  |
| Climbazole             | 97%     | 3%      | 94% | 100%| 106%    | 2%      | 104%| 107%| 3                  |
| Clomipramine           | 112%    | 6%      | 105%| 117%| 106%    | 4%      | 103%| 111%| 3                  |
| Cloperastine           | 117%    | 3%      | 113%| 119%| 110%    | 4%      | 106%| 115%| 5                  |
| Clotrimazole           | 97%     | 3%      | 95% | 100%| 98%     | 7%      | 90% | 103%| 5                  |
| Fenticonazole          | 53%     | 12%     | 41% | 64% | 66%     | 15%     | 49% | 77% | 10                  |
| Flecaïnide             | 92%     | 6%      | 87% | 98% | 101%    | 13%     | 86% | 112%| 4                  |
| Fluconazole            | 104%    | 8%      | 96% | 112%| 120%    | 5%      | 115%| 126%| 5                  |
| Haloperidol            | 86%     | 7%      | 80% | 93% | 95%     | 5%      | 89% | 98% | 5                  |
| Imazalil               | 102%    | 3%      | 98% | 104%| 98%     | 8%      | 89% | 105%| 10                  |
| Imidacloprid           | 107%    | 2%      | 91% | 120%| 112%    | 20%     | 95% | 134%| 10                  |
| Lamotrigine            | 76%     | 20%     | 63% | 99% | 108%    | 24%     | 81% | 128%| 10                  |
| Metconazole            | 97%     | 6%      | 90% | 102%| 98%     | 0%      | 98% | 99% | 6                  |
| Miconazole             | 98%     | 8%      | 93% | 108%| 99%     | 4%      | 95% | 104%| 4                  |
| Myclobutanil           | 95%     | 1%      | 95% | 96% | 102%    | 4%      | 97% | 105%| 2                  |
| N-Desethyl amiodarone  | 76%     | 3%      | 72% | 79% | 89%     | 1%      | 87% | 90% | 5                  |
| N-Desmethyl citalopram| 86%     | 14%     | 72% | 100%| 93%     | 2%      | 91% | 95% | 5                  |
| Norsertraline          | 102%    | 9%      | 97% | 112%| 104%    | 7%      | 99% | 112%| 10                  |
| O-Desmethyl venlafaxine| 86%    | 20%     | 73% | 109%| 90%     | 10%     | 79% | 97% | 3                  |
| Penconazole            | 95%     | 3%      | 92% | 98% | 101%    | 9%      | 91% | 108%| 2                  |
| Prochloraz             | 83%     | 3%      | 81% | 87% | 95%     | 11%     | 85% | 107%| 5                  |
| Propiconazole          | 96%     | 1%      | 95% | 98% | 102%    | 7%      | 95% | 110%| 5                  |
| Propranolol            | 90%     | 10%     | 81% | 100%| 107%    | 6%      | 100%| 113%| 5                  |
| Sertaconazole          | 82%     | 2%      | 80% | 83% | 89%     | 6%      | 85% | 96% | 10                  |
| Sertraline             | 108%    | 16%     | 95% | 126%| 114%    | 11%     | 101%| 122%| 5                  |
| Tebuconazole           | 94%     | 8%      | 89% | 103%| 102%    | 6%      | 96% | 106%| 5                  |
| Terbutryn              | 104%    | 4%      | 101%| 109%| 106%    | 6%      | 98% | 111%| 2                  |
| Tetraconazole          | 96%     | 3%      | 93% | 100%| 101%    | 3%      | 99% | 105%| 4                  |
| Thiabendazole          | 98%     | 42%     | 67% | 146%| 93%     | 11%     | 81% | 102%| 2                  |
| Tioconazole            | 129%    | 9%      | 123%| 140%| 108%    | 5%      | 102%| 112%| 10                  |
| Tramadol               | 101%    | 7%      | 93% | 105%| 107%    | 9%      | 97% | 112%| 2                  |
| Trazodone              | 85%     | 8%      | 76% | 92% | 87%     | 12%     | 78% | 100%| 10                  |
| Venlafaxine            | 98%     | 0%      | 98% | 98% | 106%    | 6%      | 100%| 111%| 2                  |
recover the short-chain perfluorinated compounds (perfluoropropanoic, perfluorobutanoic, and perfluorobutane sulfonic acids), data not shown. For the set of basic species (including the neonicotinoids ACE and IMI), significantly higher signal suppression effects were noticed for most compounds using the non-selective HLB extraction protocol, than following the modular approach (Fig. 2B). Finally, for neutrals, only CLO and THM presented strong signal suppression effects (normalized responses below 60%, Fig. 2C). The magnitude of this attenuation was significantly higher for HLB extracts than for those obtained with the combination of sorbents described in this research. In summary, for the raw wastewater matrix, 48 out of 64 compounds showed low MEs (normalized responses from 80 to 120%) using the modular SPE procedure, whilst only 25 species were within this interval with the SPE sorbent (Fig. 2D). In case of treated wastewater, lower differences were noticed between MEs for the modular SPE protocol and those observed for the HLB sorbent (Fig. 2D); however, the later sorbent was not able to recover short-chain perfluorinated compounds from water samples at neutral pH. Detailed data of MEs for treated wastewater are compiled in Table S3.

The accuracy of the proposed methodology was assessed with recoveries assessed for samples spiked at different concentration levels, and calculated against solvent-based standards. Values obtained for each sample and addition level, including their standard deviations, are given as supplementary information (Table S4). A summary of global recoveries (with minimum and maximum values) observed for raw and treated wastewater samples is compiled in Table 3. Out of 64 compounds considered in this study, 57 and 60 species (in raw and treated wastewater, respectively) showed overall recoveries in the range between 80 and 120%. Therefore, the use of isotopically labeled analogues permitted to compensate problems (EEs below 80%) previously highlighted for those compounds distributed between neutral and basic fractions (IMI and ACE), and most of the species affected by sorption problems. Overall, the global mean of the recoveries for each of the three groups of compounds considered in this study varied between 95 and 100%. In summary, the modular SPE method described in this study provides accuracy values, for the three kinds of compounds, similar to those achieved using previously reported conventional MM methodologies, either focused on the selective extraction of acidic compounds [12, 14], or addressing the concentration and isolation of basic drugs [11], from wastewater samples.

The last column in Table 3 summarizes the LOQs of the method for raw wastewater. For the perfluorinated carboxylic acids and organophosphorus species, the global LOQs were determined by responses observed in procedural blanks. For the rest of compounds, procedural LOQs were controlled by instrumental LOQs (Table 1) and the performance of the SPE extraction step. With the exception of two phenoxy acid herbicides, the procedural LOQs varied between 2 and 10 ng L\(^{-1}\). Overall, LOQs shown in Table 3 are in the range of values reported in previous studies using LC–MS/MS as determination technique after SPE either using HLB type [4, 6] or a single MM cartridge [10, 11]. Obviously, none of these previous methods covered the range of polarities considered in the current research.

### Table 3 (continued)

| Compound                        | Raw wastewater Mean (RSD) | Min | Max | LOQs ng L\(^{-1}\) |
|---------------------------------|--------------------------|-----|-----|-------------------|
| Neutrals                        |                          |     |     |                   |
| Clothianidin                    | 90% (3%)                 | 77% | 97% | 5                 |
| Cresyl diphenyl phosphate       | 97% (3%)                 | 95% | 99% | 3                 |
| Dimoxystrobin                   | 109% (2%)                | 108%| 110%| 10                |
| Octyl isothiazolinone           | 106% (5%)                | 101%| 112%| 5                 |
| Tris(2-chloroethyl) phosphate   | 79% (1%)                 | 78% | 79% | 10                |
| Tris(1-chloro-2-propyl) phosphate| 105% (1%)               | 98% | 111%| 10                |
| Triclosan                       | 94% (0%)                 | 93% | 95% | 5                 |
| Thiamethoxam                    | 98% (0%)                 | 95% | 102%| 3                 |
| Tributoxylethyl phosphate       | 103% (3%)                | 88% | 118%| 10                |
| Tributyl phosphate              | 86% (1%)                 | 74% | 93% | 10                |
| Triphenyl phosphate             | 97% (1%)                 | 90% | 107%| 10                |
Positive identifications were based on retention time and Q2/ Q1 matches (0.1 min and ± 30%, respectively) with calibration standards. A group of 46 compounds was quantified in at least one of the processed samples. Their concentrations (average values for duplicate extractions) are shown in Table S5. Among them, 33 species reached average levels above, or very close to 20 ng L\(^{-1}\), either in raw or in treated wastewater.

Figure 3A shows the sum of concentrations for acidic, basic, and neutral pollutants in wastewater samples. The contribution of species detected, but remaining below method LOQs, was not considered. In most of the samples, the sum of concentrations of acids was higher than those of bases and neutrals. On the other hand, the overall concentration of bases was that showing the lower reduction during wastewater treatment. Figure 3B displays the average concentrations (logarithmic scale) of compounds found at levels above 20 ng L\(^{-1}\) in raw and treated wastewater. In the first matrix, 16 species showed average levels above 100 ng L\(^{-1}\). Within this group, we found two organophosphorus compounds (TCP and TBEP), several cardiovascular drugs (in most cases ARA-II compounds and flecainide), opioids (such as TRA), different psychiatric drugs, and their human metabolites (VEN, O-DVEN, CIT, and N-DCIT). Among pesticides, terbutryn, imidaclorprid, thiamethoxam, and thiamethadazole were also ubiquitous in wastewater, with average concentrations in the range from 30 to 100 ng L\(^{-1}\).

Figure 3C shows the median value of the apparent removal efficiencies for those compounds found above their LOQs in at least four of the six pairs of composite sewage water samples. Compounds are sorted from higher to lower removal efficiencies. Several pollutants displayed very low (below 20%), even negative, removal efficiencies, leading to similar, even higher, concentrations in treated than in raw wastewater. In case of pharmaceuticals, a potential explanation for negative removal rates is de-conjugation during wastewater treatment, as reported for lamotrigine [21]. For moderately lipophilic compounds, negative removal rates might be an artifact caused by differential sorption of these species on particulate matter existing in raw and treated wastewater, either at STPs, or during transport. Whatever the exact source, similar trends have been already reported in case of perfluorooctanoic acid [22]. A particular case of compound generated in the STPs was VALA. This species is a biodegradation product of some ARA-II drugs, particularly of VAL [12]. On average, its concentration in treated wastewater was 10-times higher than in the influent of STPs (Fig. 3B and C). In fact, VALA was the compound showing the highest average concentration in the effluents of the STPs. It is also worth noting that some compounds showing high apparent removal efficiencies (i.e., TBEP, telmisartan, losartan, TCS, and clindamizole) have been previously reported in sludge at moderate-to-high concentrations [23, 24]. Thus, sludge sorption might be responsible, at least in part, for the apparent degradation efficiencies depicted in Fig. 3C.

The efficiency of the modular SPE protocol to isolate additional compounds in a single fraction, eluted from the combination of SPE sorbents, was assessed using a LC-ESI-QTOF-MS system. To this end, a list of suspected targets was investigated in every SPE fraction from three different raw wastewater extracts. Their normalized responses (Table S6) confirmed trends observed for the previous suite of targets. Compounds with a carboxylic acid, or a stronger acid functionality, were recovered in the fraction from the WAX cartridge, no matter the co-existence of basic moieties in their molecules (e.g., atorvastatin, furosemide, and diclofenac). Slightly (caffeine) and strong basic compounds (cocaine, ephedrine, amisulpride) were trapped by the pure cationic exchange SCX sorbent. Finally, the set of investigated phenols (acetaminophen, benzophenone-3, methyl and propyl paraben) was mostly recovered with neutrals given their weak and null interactions with WAX and SCX sorbents, respectively.

**Conclusions**

The modular SPE configuration described in this research permitted the effective concentration of a suite of 64 compounds, with log D values comprised between – 1.95 and 4.5 units, from wastewater samples. Compared to an HLB-type sorbent, the described setup allowed the effective retention of relevant groups of polar, anionic pollutants, without requiring acidification of water samples. Considering the obtained MEs, the fraction of bases showed a much lower complexity than that obtained using the HLB-type sorbent. To the best of our knowledge, this study reports for the first time the successful extraction and fractionation of acids, bases, and neutrals from water samples combining commercially available cartridges of different sorbents. In addition to its qualitative applications, the proposed SPE setup might be useful in non-target screening studies, to reduce the number of potential candidates existing in each fraction obtained from the same water sample. Quantitative data obtained for integrated water samples highlighted several pharmaceuticals poorly removed, even generated, during wastewater treatment. These species might serve as markers to assess the impact of urban wastewater in surface water reservoirs.
Supplementary Information  The online version contains supplementary material available at https://doi.org/10.1007/s00216-022-04066-8.

Acknowledgements  We acknowledge Agilent for providing access to the LC-ESI-MS/MS instrumentation employed in this study.

Funding  Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study was supported by Spanish Government and Xunta de Galicia through grants PGC2018-094613-B-I00 and ED431C 2021/06, both co-funded by the EU FEDER program.

Declarations

Conflict of interest  The authors declare no competing interests.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Tran NH, Reinhard M, Gin KYH. Occurrence and fate of emerging contaminants in municipal wastewater treatment plants from different geographical regions-a review. Water Res. 2018;133:182–207. https://doi.org/10.1016/j.watres.2017.12.029.
2. McCance W, Jones OAH, Edwards M, Surapaneni A, Chadalavada S, Currell M. Contaminants of emerging concern as novel groundwater tracers for delineating wastewater impacts in urban and peri-urban areas. Water Res. 2018;146:118–33. https://doi.org/10.1016/j.watres.2018.09.013.
3. Núñez M, Borrull F, Pocurull E, Fontanals N. Sample treatment for the determination of emerging organic contaminants in aquatic organisms. TrAC - TRENDS ANAL CHEM. 2017;97:136–45. https://doi.org/10.1016/j.trac.2017.09.007.
4. Rodil R, Quintana JB, López-Mahía P, Muniategui-Lorenzo S, Prada-Rodríguez D. Multi-residue analytical method for the determination of emerging pollutants in water by solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2009;1216:2958–69. https://doi.org/10.1016/j.chroma.2009.02.040.
5. Čizmić M, Babić S, Kaštelan-Macan M. Multi-class determination of pharmaceuticals in wastewaters by solid-phase extraction and liquid chromatography tandem mass spectrometry. Anal Bioanal Chem. 2015;407:4229–45. https://doi.org/10.1007/s00216-015-8654-x.
6. Dasenaki ME, Thomaidis NS. Multianalyte method for the determination of pharmaceuticals in wastewater samples using solid-phase extraction and liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2015;407:4229–45. https://doi.org/10.1007/s00216-015-8654-x.
7. Fontanals N, Borrull F, Marcé RM (2020) Mixed-mode ion-exchange polymeric sorbents in environmental analysis. J Chromatogr A 1609. https://doi.org/10.1016/j.chroma.2019.460531
8. Köke N, Zahn D, Knepper TP, Frömel T. Multi-layer solid-phase extraction and evaporation—enrichment methods for polar organic chemicals from aqueous matrices. Anal Bioanal Chem. 2018;410:2403–11. https://doi.org/10.1007/s00216-018-0921-1.
9. Casado J, Rodríguez I, Ramil M, Cela R. Selective determination of antimycotic drugs in environmental water samples by mixed-mode solid-phase extraction and liquid chromatography quadrupole time-of-flight mass spectrometry. J Chromatogr A. 2014;1339:42–9. https://doi.org/10.1016/j.chroma.2014.02.087.
10. Batt AL, Kostich MS, Lazorchak JM. Analysis of ecologically relevant pharmaceuticals in wastewater and surface water using selective solid-phase extraction and UPLC-MS/MS. Anal Chem. 2008;80:5021–30. https://doi.org/10.1021/ac800066n.
11. Kasprzyk-Hordern B, Dinsdale RM, Guwy AJ. Multi-residue method for the determination of basic/neutral pharmaceuticals and illicit drugs in surface water by solid-phase extraction and ultra performance liquid chromatography-positive electrospray ionisation tandem mass spectrometry. J Chromatogr A. 2007;1161:132–45. https://doi.org/10.1016/j.chroma.2007.05.074.
12. Castro G, Rodríguez I, Ramil M, Cela R. Selective determination of sartan drugs in environmental water samples by mixed-mode solid-phase extraction and liquid chromatography tandem mass spectrometry. Chemosphere. 2019;224:562–71. https://doi.org/10.1016/j.chemosphere.2019.02.137.
13. González-Mariño I, Quintana JB, Rodríguez I, González-Díez M, Cela R. Screening and selective quantification of illicit drugs in wastewater by mixed-mode solid-phase extraction and quadrupole-time-of-flight liquid chromatography-mass spectrometry. Anal Chem. 2012;84:1708–17. https://doi.org/10.1021/ac202989e.
14. Montes R, Rodil R, Placer L, Wilms JM, Cela R, Quintana JB. Applicability of mixed-mode chromatography for the simultaneous analysis of C1–C18 perfluoroalkylated substances. Anal Bioanal Chem. 2020;412:4849–56. https://doi.org/10.1007/s00216-020-04343-w.
15. Nadal JC, Dargo S, Borrull F, Cormack PAG, Fontanals N, Marcé RM. Hypercrosslinked polymer microspheres decorated with anion- and cation-exchange groups for the simultaneous solid-phase extraction of acidic and basic analytes from environmental waters. J Chromatogr A. 2022;1661:462715. https://doi.org/10.1016/j.chroma.2021.462715.
16. Deeb AA, Schmidt TC. Tandem anion and cation exchange solid phase extraction for the enrichment of micropollutants and their transformation products from ozonation in a wastewater treatment plant. Anal Bioanal Chem. 2016;408:4219–32. https://doi.org/10.1007/s00216-016-9523-y.
17. Salas D, Borrull F, Fontanals N, Marcé RM. Combining cationic and anionic mixed-mode sorbents in a single cartridge to extract basic and acidic pharmaceuticals simultaneously from environmental waters. Anal Bioanal Chem. 2018;410:459–69. https://doi.org/10.1007/s00216-017-0736-5.
18. Commission E. COMMISSION IMPLEMENTING DECISION (EU) 2020/1161-4 August 2020-establishing a watch list of substances for union-wide monitoring in the field of water policy pursuant to Directive 2008/105/EC of the European Parliament and of the Council. Off J Eur Union L. 2020:257:32–5.
19. Hanari N, Itoh N, Ishikawa K, Yarita T, Numata M. Variation in concentration of perfluorooctanoic acid in methanol solutions during storage. Chemosphere. 2014;94:116–20. https://doi.org/10.1016/j.chemosphere.2013.09.040.

© Springer
20. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Anal Chem. 1998;70:882–9. https://doi.org/10.1021/ac971078+.

21. Zonja B, Pérez S, Barceló D. Human metabolite lamotrigine-N2-glucuronide is the principal source of lamotrigine-derived compounds in wastewater treatment plants and surface water. Environ Sci Technol. 2016;50:154–64. https://doi.org/10.1021/acs.est.5b03691.

22. Rodríguez-Varela M, Durán-Álvarez JC, Jiménez-Cisneros B, Zamora O, Prado B. Occurrence of perfluorinated carboxylic acids in Mexico City’s wastewater: a monitoring study in the sewerage and a mega wastewater treatment plant. Sci Total Environ. 2021;774:145060. https://doi.org/10.1016/j.scitotenv.2021.145060.

23. Celano R, Rodríguez I, Cela R, Rastrelli L, Piccinelli AL. Liquid chromatography quadrupole time-of-flight mass spectrometry quantification and screening of organophosphate compounds in sludge. Talanta. 2014;118:312–20. https://doi.org/10.1016/j.talanta.2013.10.024.

24. Castro G, Carpinteiro I, Rodríguez I, Cela R. Determination of cardiovascular drugs in sewage sludge by matrix solid-phase dispersion and ultra-performance liquid chromatography tandem mass spectrometry. Anal Bioanal Chem. 2018;410:6807–17. https://doi.org/10.1007/s00216-018-1268-3.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.